GeoVax Labs Inc
Filed Sep 6, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Sep 6, 2024
GOVX$0.16-0.1%Stored close · as of Nov 6, 2026
Contents
Clinical Development Programs
| Product | Indication | Clinical Trial | Status |
|---|---|---|---|
| BARDA Project NextGen 10,000 Patient Comparison Study | Phase 2b Initiation pending | ||
| Primary Vaccine for Immunocompromised/Stem Cell Transplant Patients (NCT04977024) | Phase 2 Currently enrolling | ||
| GEO-CM04S1 | COVID-19 | Booster Vaccine for Immunocompromised/Chronic Lymphocytic Patients (NCT05672355) | Phase 2 Currently enrolling |
| Booster Vaccine for Healthy Adults (NCT04639466) | Phase 2 Enrollment closed | ||
| Advanced Head & Neck Cancer* | Effect on Targeted Tumors (NCT03754933) | Phase 1b/2a Completed | |
| Gedeptin® | Squamous Cell Head & Neck Cancer | First Recurrence Therapy in Combination with Immune Checkpoint Inhibitor | Phase 2 Planning |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.